NCT06993870View on ClinicalTrials.gov

Phase I Study of HBT-708 for Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

June 28, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

HBT-708

bispecific antibody

Trial Locations (1)

200000

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY